Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report)'s stock price traded down 4% during trading on Thursday . The stock traded as low as $17.43 and last traded at $17.42. 4,263,895 shares traded hands during trading, a decline of 57% from the average session volume of 10,010,039 shares. The stock had previously closed at $18.15.
Analyst Ratings Changes
Several research firms have issued reports on TEVA. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price objective for the company from $21.00 to $23.00 in a research note on Monday, May 12th. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Bank of America lifted their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Finally, Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday. They issued a "buy" rating and a $25.00 price objective on the stock. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of "Buy" and a consensus price target of $24.50.
Read Our Latest Stock Report on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Trading Down 4.3%
The stock has a market cap of $19.01 billion, a PE ratio of -11.57, a P/E/G ratio of 1.44 and a beta of 0.62. The business's fifty day moving average is $15.52 and its 200 day moving average is $17.37. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The firm had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.99 billion. During the same quarter in the previous year, the firm earned $0.48 earnings per share. The firm's revenue was up 1.9% on a year-over-year basis. As a group, analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.
Institutional Trading of Teva Pharmaceutical Industries
Several institutional investors and hedge funds have recently modified their holdings of the business. Robeco Institutional Asset Management B.V. raised its position in shares of Teva Pharmaceutical Industries by 7.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock valued at $10,983,000 after buying an additional 33,277 shares during the last quarter. Pinnbrook Capital Management LP acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at $4,966,000. Asset Management One Co. Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 14.6% during the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company's stock valued at $10,414,000 after acquiring an additional 58,413 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Teva Pharmaceutical Industries by 2,018.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,097,096 shares of the company's stock valued at $23,368,000 after purchasing an additional 1,045,305 shares in the last quarter. Finally, Capital Wealth Planning LLC grew its holdings in Teva Pharmaceutical Industries by 8.8% during the 4th quarter. Capital Wealth Planning LLC now owns 246,601 shares of the company's stock valued at $5,435,000 after purchasing an additional 20,016 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.
Teva Pharmaceutical Industries Company Profile
(
Get Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Featured Articles
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
